MOXR 0916

Drug Profile

MOXR 0916

Alternative Names: MOXR0916; RG 7888

Latest Information Update: 25 Jul 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urogenital cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Mar 2017 Phase-II clinical trials in Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in United Kingdom, Canada, Portugal (IV) (NCT03029832) after March 2017
  • 09 Mar 2017 Phase-II clinical trials in Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT03029832)
  • 20 Jan 2017 Genentech plans a phase II trial for Urogenital cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) (IV) (NCT03029832)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top